Trials / Terminated
TerminatedNCT03374085
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multi-center, international, Phase 1/2 study to assess the safety, PK and efficacy of CC-92480 monotherapy and in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM). All eligible subjects must be previously treated with at least 3 prior regimens including lenalidomide, pomalidomide, a proteasome inhibitor and an anti-CD38 antibody and be refractory to their last line of therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-92480 | CC-92480 |
| DRUG | Dexamethasone | Dexamethasone |
Timeline
- Start date
- 2018-02-06
- Primary completion
- 2025-08-20
- Completion
- 2025-10-23
- First posted
- 2017-12-15
- Last updated
- 2026-02-09
Locations
54 sites across 11 countries: United States, Australia, Belgium, Canada, Denmark, Finland, Greece, Japan, South Korea, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03374085. Inclusion in this directory is not an endorsement.